Histone Deacetylase Inhibitors
"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
| Descriptor ID |
D056572
|
| MeSH Number(s) |
D27.505.519.389.360
|
| Concept/Terms |
Histone Deacetylase Inhibitors- Histone Deacetylase Inhibitors
- Deacetylase Inhibitors, Histone
- Inhibitors, Histone Deacetylase
- Histone Deacetylase Inhibitor
- Deacetylase Inhibitor, Histone
- Inhibitor, Histone Deacetylase
- HDAC Inhibitors
- Inhibitors, HDAC
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".
This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 12 | 6 | 18 |
| 2018 | 13 | 7 | 20 |
| 2019 | 3 | 2 | 5 |
| 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.
-
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol. 2021 May 05; 898:173988.
-
Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19. Sci Rep. 2021 02 09; 11(1):3379.
-
Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-ß signalling in COVID-19 survivors. Life Sci. 2021 Feb 01; 266:118883.
-
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use? Eur J Cancer. 2020 09; 136:1-3.
-
Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role. Curr Med Chem. 2020; 27(36):6099-6111.
-
Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators. J Virol. 2019 11 01; 93(21).
-
Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines. Cancer Lett. 2019 Oct 01; 461:90-101.
-
Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis. J Allergy Clin Immunol. 2019 11; 144(5):1242-1253.e7.
-
Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma. Anticancer Res. 2019 Mar; 39(3):1119-1127.
-
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro. J Diabetes Res. 2019; 2019:8520856.